Form 4: Albert Bourla Logs Minor Deferred-Comp Transaction at Pfizer
Rhea-AI Filing Summary
Pfizer Inc. (PFE) – Form 4 insider filing shows Chairman & CEO Albert Bourla acquired a de minimis 26 phantom stock units on 31-Jul-2025 through the company’s Non-Funded Deferred Compensation and Supplemental Savings Plan (SSP).
• Transaction code: A (acquisition).
• Unit price: $23.29.
• Total value: ≈ $606.
• Post-transaction holdings: 731,620 phantom stock units, held directly (D).
Phantom units are cash-settled and do not alter the public share count; the participant may transfer them into another investment option at any time. No common stock transactions were reported in Table I.
Materiality: The addition represents less than 0.01 % of Bourla’s existing derivative position and has no discernible impact on Pfizer’s capital structure or governance.
Positive
- None.
Negative
- None.
Insights
TL;DR: Tiny deferred-comp addition; no investment impact.
The 26-unit SSP allocation (~$600) is immaterial versus Bourla’s 731k phantom units and has no effect on float, earnings, or insider sentiment indicators. Rating: neutral.
TL;DR: Routine Form 4, governance status unchanged.
This filing simply documents ongoing deferred-comp accrual. Because units are cash-settled on separation, there is no dilution risk or voting power shift. No red flags detected.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Phantom Stock Units SSP | 26 | $23.29 | $605.54 |
Footnotes (1)
- Each unit represents one phantom share of common stock. These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time.